Results 1 to 10 of about 10,088 (118)
Network pharmacology and integrative bioinformatics analyses identify PDE1A as a key target of pirfenidone in idiopathic pulmonary fibrosis. [PDF]
PLoS ONEPirfenidone, an antifibrotic agent, has been shown to be effective in the treatment of idiopathic pulmonary fibrosis (IPF). However, the exact mechanism of action and clinical efficacy require further investigation and validation. This study commenced by
Jing Wu +5 more
doaj +2 more sources
Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study [PDF]
The Korean Journal of Internal Medicine, 2022 Background/Aims Pirfenidone slows the progression of idiopathic pulmonary fibrosis (IPF). We investigated its efficacy and safety in terms of dose and disease severity in real-world patients with IPF.
Hyeontaek Hwang +9 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by progressive and irreversible loss of lung function. Clinically safe and efficacious drug treatments for IPF are lacking.
Meishan Han +9 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Endothelial cell dysfunction and fibrosis are associated with worsening of the prognosis in patients with cardiovascular disease. Pirfenidone has a direct antifibrotic effect, but vasodilatation may also contribute to the effects of pirfenidone ...
Lilliana Beck +13 more
doaj +1 more source
BMC Pulmonary Medicine, 2023 Background Numerous studies have demonstrated the potential of pirfenidone to enhance the prognosis of patients afflicted with idiopathic pulmonary fibrosis (IPF).
Xiu-Li Zhang, Ying Cao, Bo Zheng
doaj +1 more source
PLoS ONE, 2021 BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown etiology. In several randomized clinical trials, and in the clinical practice, pirfenidone is used to effectively and safely treat IPF ...
Eung Gu Lee +8 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease.
Tomohito Okano +21 more
doaj +1 more source
PLoS ONE, 2023 IntroductionAlthough pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events.
Jiwon Kim +3 more
doaj +2 more sources
Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn. [PDF]
PLoS ONE, 2013 To evaluate the effects of pirfenidone nanoparticles on corneal re-epithelialization and scarring, major clinical challenges after alkali burn.Effect of pirfenidone on collagen I and α-smooth muscle actin (α-SMA) synthesis by TGFβ induced primary corneal
Sushovan Chowdhury +5 more
doaj +1 more source
Pirfenidone combined with N-acetylcysteine in treatment of pulmonary fibrosis: a case report and literature review [PDF]
Xin yixue, 2022 Objective To evaluate the efficacy and safety of pirfenidone combined with N-acetylcysteine （NAC） in the treatment of pulmonary fibrosis, aiming to provide basis for clinical medication. Methods Clinical data of 1 patient with combined pulmonary fibrosis
Li Wenjuan, Zhang Liyi, Zhou Yuqi
doaj +1 more source